Business
Exelixis develops and commercializes cancer medicines.
Exelixis delivered growth, a 38% margin and nearly $900 million of free cash flow from its oncology franchise.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 7.0%OK
- Profitability — Net income grew 50.1% to $782.57M from $521.267MOK
- Cash flow — Free cash flow grew 30.4% to $875.838M from $671.536MOK
- Margins — Operating margin expanded 971 bps to 37.59%OK
- Accounting — Exceptional oncology cash generationNote
- Insiders — 1 purchases and 25 salesOK
Where the revenue comes from
Fiscal 2025, as EXELIXIS, INC. reports it. History and quarterly detail are in the app.
- Gross product revenues$3.0B
- Net product revenues$2.1B
- CABOMETYX$2.1B
- License revenues$214.4M
- Collaboration services revenues$197.3M
Leadership changes
From EXELIXIS, INC.'s own filings, the day they're filed.
- Amy C. Peterson · Chief Medical Officer · departureeff. 2025-08-29
- Dana T. Aftab · President · appointmenteff. 2025-08-29
- Jacqueline Wright · Directors · departureeff. 2024-03-27
Latest filings
- 8-K · Company announcement2026-08-31
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-05-29
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about EXELIXIS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.